Nonalcoholic fatty liver disease (NAFLD)
Nonalcoholic fatty liver disease and obstructive sleep apnea
28
Dihydroceramides in Triglyceride-Enriched VLDL Are Associated with Nonalcoholic Fatty Liver Disease Severity in Type 2 Diabetes
17
Nonalcoholic Fatty Liver Disease: Modulating Gut Microbiota to Improve Severity?
38
Burn after feeding. An old uncoupler of oxidative phosphorylation is redesigned for the treatment of nonalcoholic fatty liver disease.
15
Magnetic resonance-based biomarkers in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
10
Treatments in Covid-19 patients with pre-existing metabolic dysfunction-associated fatty liver disease: A potential threat for drug-induced liver injury?
32
View of Non Alcoholic Fatty Liver Disease and Non Alcoholic Steato-Hepatitis are Multisystemic Diseases: Review for Intensivists
12
Specificities of Human Hepatocellular Carcinoma Developed on Non-Alcoholic Fatty Liver Disease in Absence of Cirrhosis Revealed by Tissue Extracts 1H-NMR Spectroscopy
18
Elevated serum liver-type fatty acid binding protein levels in non-acetaminophen acute liver failure patients with organ dysfunction.
13
Impact of bacterial probiotics on obesity, diabetes and non-alcoholic fatty liver disease related variables: a systematic review and meta-analysis of randomised controlled trials
13
Autochthonous liver cystic hydatid: Past or actual French shepherd's disease?
4
SERPINA1 Z allele is associated with cystic fibrosis liver disease
25
Specificities of Hepatocellular Carcinoma Developed on Non Alcoholic Fatty Liver Disease in Absence of Cirrhosis Revealed by Tissue 1H-NMR Spectroscopy
2
Nutrigenomics of high fat diet induced obesity in mice suggests relationships between susceptibility to fatty liver disease and the proteasome
13
Brain edema in acute liver failure and chronic liver disease: Similarities and differences
20
Tight junction proteins in gastrointestinal and liver disease
61
AMPK Re-Activation Suppresses Hepatic Steatosis but its Downregulation Does Not Promote Fatty Liver Development
17
DEP domain-containing mTOR-interacting protein suppresses lipogenesis and ameliorates hepatic steatosis and acute-on-chronic liver injury in alcoholic liver disease
31
Awareness of the severity of liver disease re-examined using software-combined biomarkers of liver fibrosis and necroinflammatory activity
12
Rôle du régulateur du cycle cellulaire p16INK4a dans le développement du diabète de type 2 et dans les maladies métaboliques du foie gras ou NAFLD (Non-Alcoholic Fatty Liver Disease) : rôle de p16INK4a dans le contrôle de la néoglucogenèse hépatique et dans le développement de la stéatose hépatique non alcoolique.
117